Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $94000.0.

  • Fulcrum Therapeutics' Capital Expenditures fell 3815.79% to $94000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $257000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $278000.0 for FY2024, which is 4527.56% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Capital Expenditures stood at $94000.0 for Q3 2025, which was down 3815.79% from $65000.0 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Capital Expenditures registered a high of $847000.0 during Q1 2022, and its lowest value of $28000.0 during Q1 2024.
  • Moreover, its 5-year median value for Capital Expenditures was $171000.0 (2023), whereas its average is $271823.5.
  • In the last 5 years, Fulcrum Therapeutics' Capital Expenditures soared by 29462.37% in 2021 and then crashed by 8362.57% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Capital Expenditures (Quarter) stood at $519000.0 in 2021, then crashed by 77.65% to $116000.0 in 2022, then crashed by 33.62% to $77000.0 in 2023, then rose by 27.27% to $98000.0 in 2024, then decreased by 4.08% to $94000.0 in 2025.
  • Its Capital Expenditures was $94000.0 in Q3 2025, compared to $65000.0 in Q2 2025 and $98000.0 in Q4 2024.